RARE - Ultragenyx Pharmaceutical Inc.
IEX Last Trade
56.78
-0.180 -0.317%
Share volume: 754,442
Last Updated: Fri 30 Aug 2024 09:59:54 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$56.96
-0.18
-0.32%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-02-17 | 2023-05-05 | 2023-08-04 | 2023-11-03 | 2024-02-21 | 2024-05-03 | 2024-08-02 | |
| Assets | |||||||||
| Total Assets | 1.618 B | 1.545 B | 1.383 B | 1.311 B | 1.238 B | 1.491 B | 1.307 B | 1.618 B | |
| Current Assets | 1.013 B | 883.899 M | 766.336 M | 702.137 M | 599.188 M | 732.184 M | 595.967 M | 964.640 M | |
| Inventories | 21.849 M | 26.766 M | 26.616 M | 28.256 M | 31.802 M | 33.969 M | 35.907 M | 40.137 M | |
| Other Current Assets | 70.980 M | 68.926 M | 67.375 M | 51.377 M | 46.029 M | 47.616 M | 47.727 M | 54.700 M | |
| Short Term Investments | 70.980 M | 68.926 M | 67.375 M | 51.377 M | 46.029 M | 47.616 M | 47.727 M | 54.700 M | |
| Total Receivables | 31.164 M | 40.445 M | 42.991 M | 70.523 M | 79.263 M | 73.390 M | 100.253 M | 105.982 M | |
| Current Cash | 888.675 M | 747.762 M | 629.354 M | 551.981 M | 442.094 M | 577.209 M | 412.080 M | 763.821 M | |
| Total Non-current Assets | 605.806 M | 661.545 M | 617.068 M | 609.173 M | 638.952 M | 758.829 M | 711.113 M | 653.797 M | |
| Property Plant Equipment | 234.614 M | 259.726 M | 277.873 M | 288.990 M | 296.811 M | 290.566 M | 285.111 M | 278.707 M | |
| Other Assets | 18.285 M | 16.846 M | 22.259 M | 26.489 M | 27.896 M | 57.685 M | 59.970 M | 53.772 M | |
| Intangible Assets | 158.401 M | 160.105 M | 159.171 M | 158.237 M | 157.302 M | 166.271 M | 165.045 M | 166.243 M | |
| Goodwill | 44.406 M | 44.406 M | 44.406 M | 44.406 M | 44.406 M | 44.406 M | 44.406 M | 44.406 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.618 B | 1.545 B | 1.383 B | 1.311 B | 1.238 B | 1.491 B | 1.307 B | 1.618 B | |
| Total liabilities | 1.150 B | 1.193 B | 1.163 B | 1.182 B | 1.206 B | 1.216 B | 1.167 B | 1.186 B | |
| Total current liabilities | 227.361 M | 261.210 M | 218.179 M | 244.379 M | 253.978 M | 280.437 M | 245.575 M | 272.866 M | |
| Accounts Payable | 23.533 M | 43.274 M | 58.981 M | 42.115 M | 33.357 M | 42.114 M | 40.972 M | 59.807 M | |
| Other liabilities | 866.113 M | 880.259 M | 895.737 M | 891.389 M | 886.226 M | 874.530 M | 863.204 M | 857.354 M | |
| Current long term debt | 0.000 | 183.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 866.113 M | 880.259 M | 895.737 M | 891.389 M | 886.226 M | 874.530 M | 863.204 M | 857.354 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 468.829 M | 352.494 M | 220.481 M | 129.030 M | 31.714 M | 275.414 M | 140.264 M | 432.418 M | |
| Common stock | 70.054 M | 70.161 M | 70.368 M | 70.898 M | 71.664 M | 81.244 M | 84.286 M | 86.581 M | |
| Retained earnings | -2.629 B | -2.781 B | -2.945 B | -3.105 B | -3.264 B | -3.388 B | -3.558 B | -3.690 B |